14 results on '"Moylan, Eugene"'
Search Results
2. Polypharmacy and the use of low or limited value medications in advanced cancer.
- Author
-
Haider, Sana, Descallar, Joseph, Moylan, Eugene, and Wei Chua
- Subjects
- *
ANTIHYPERTENSIVE agents , *ACQUISITION of data methodology , *CONFIDENCE intervals , *POLYPHARMACY , *RETROSPECTIVE studies , *HYPOGLYCEMIC agents , *INAPPROPRIATE prescribing (Medicine) , *MEDICAL records , *DESCRIPTIVE statistics , *TUMORS , *ODDS ratio , *COMORBIDITY - Abstract
Background: Patients with advanced malignancy are often on medications for co-morbidities, including those for primary or secondary prevention. The benefit from these medications can be limited and may result in adverse effects, interact with medications used for the malignancy or associated symptoms, increase pill burden and reduce quality of life. Aims: To evaluate the proportion of patients with advanced malignancy that were continued on low or limited value medications and identify the factors associated with this. We also sought to determine how prevalent polypharmacy was within this group of patients and the factors associated with this. Methods: A retrospective chart review was conducted of patients with incurable malignancy admitted under medical oncology at Liverpool Hospital over a 90-day period. Demographic variables, co-morbidities, disease related parameters and medications were reviewed. Criteria were established to identify low or limited value medications. Results: Seventy-eight patients were identified between September and December 2018. Thirty-day mortality was 33%. Sixty-five percent of the cohort was on five or more medications and 24% on 10 or more. One low or limited value medication was reported in 36% and 20% were on two or more. Age =60 years was associated with a risk of being on at least one unnecessary medication. Patients with fewer co-morbidities and those in their last 3 months of life were significantly less likely to have polypharmacy. Nine percent of the cohort was on three or more antihypertensives and 6% of patients were on three or more oral hypoglycaemics. Conclusion: Polypharmacy and continued prescribing of low or limited value medications was identified in a high proportion of patients. Further studies are needed to assess the impact of continuing these medications, as well as investigation of patient and physician attitudes towards de-escalation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Patterns of care and outcomes among triple‐negative early breast cancer patients in South Western Sydney.
- Author
-
Naher, Sayeda, Tognela, Annette, Moylan, Eugene, Adams, Diana H., and Kiely, Belinda E.
- Subjects
- *
BREAST cancer prognosis , *BREAST tumor treatment , *FLUOROURACIL , *DOCETAXEL , *CYCLOPHOSPHAMIDE , *DUCTAL carcinoma , *EPIRUBICIN , *BREAST tumors , *CANCER patient medical care , *CANCER relapse , *CANCER treatment , *COMBINED modality therapy , *MEDICAL care , *RADIOTHERAPY , *TUMOR classification , *SPECIALTY hospitals , *TREATMENT effectiveness , *ELECTRONIC health records , *KAPLAN-Meier estimator , *THERAPEUTICS - Abstract
Abstract: Background: Triple‐negative breast cancer (TNBC) represents 12‐24% of all breast cancer and carries a poor prognosis upon recurrence. Little is known of the treatment, or timing and frequency of recurrences outside of a clinical trial. Aim: We describe the patterns of care and outcomes of women with TNBC treated at two cancer centres in Sydney, NSW, Australia, to help oncologists talk to women with this subtype of breast cancer about their likely prognosis. Methods: We searched the electronic medical record for women with stages I–III TNBC diagnosed from 2006 to 2014. For each woman, we recorded demographics, tumour characteristics, treatment details, recurrences and survival using the Kaplan–Meier method. Results: We identified 137 women with a median age of 55 years (interquartile range (IQR) 44–63). The median tumour size was 25 mm (IQR 16–35). Most women had grade 3 (92%) and ductal carcinomas (89%), and 35% were node positive; 113 (82%) patients received (neo)adjuvant chemotherapy. The most prescribed regimens for node‐negative tumours were: fluorouracil, epirubicin and cyclophosphamide (FEC) × 6 (23pts, 35%), and for node‐positive tumours, FEC‐Docetaxel (18pts, 40%). Adjuvant radiotherapy was delivered to 114 (83%) patients. After a median follow up of 40 months, 17 patients (12%) had a recurrence. All but one recurrence (94%) occurred within 3 years of diagnosis. Twelve women received palliative chemotherapy, and 14 women have died. The median survival from the time of recurrence was 18 months (IQR 5–26). Seven women (5%) had a documented
BRCA1 mutation, and four women (3%) had a documentedBRCA2 mutation. Conclusions: TNBC affects women at a relatively young age and tends to recur early. Survival following metastatic disease is short, and more effective therapies are needed. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. The Development of a Model of Outpatient Chemotherapy Delivery – Chemotherapy Basic Treatment Equivalent (CBTE)
- Author
-
Delaney, Geoff, Bin Jalaludin, Geoff, Moylan, Eugene, and Barton, Michael
- Subjects
- *
DRUG therapy , *THERAPEUTICS - Abstract
The aims of this study were to study the patient-, tumour- and treatment-related factors that significantly impact on treatment episode duration for outpatient chemotherapy treatment delivery, and to develop a new measure of outpatient chemotherapy throughput that considers variations in treatment duration compared with the older measures of patients treated per day. A pilot study in our institution randomly measured the duration of outpatient chemotherapy delivery for 266 occasions of service. Patient, tumour and treatment factors were collected and assessed for their impact on treatment duration using multivariate analysis. A new model of outpatient chemotherapy was developed using various modeling processes. Median treatment duration was 90 min. Significant factors that impacted on treatment duration were the chemotherapy regimen, type of infusion, patient age and whether the patients required a community nurse to be organized. A measure was developed (Chemotherapy Basic Treatment Equivalent or CBTE) that considers the variations in treatment duration and showed that although the daily number of patients treated in our department each day remained stable, there were wide fluctuations in workload when variations in treatment duration were considered. A new measure of chemotherapy workload has therefore been proposed although further testing across departments is required. If broadly implemented this could substantially improve resource planning, resource use and patient satisfaction as it considers variations in treatment duration, which is not previously considered in chemotherapy throughput statistics. Copyright 2002 The Royal College of Radiologists. Published by Elsevier Science Ltd. All rights reserved. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
5. Concurrent Paraneoplastic Dermatomyositis and Acquired C1 Esterase Inhibitor Deficiency in Primary Laryngeal Small Cell Carcinoma.
- Author
-
Nindra, Udit, Nguyen, Katie, Hong, JunHee, Bray, Victoria, and Moylan, Eugene
- Subjects
- *
SMALL cell carcinoma , *DERMATOMYOSITIS , *PARANEOPLASTIC syndromes , *HEAD & neck cancer , *INTRAVENOUS therapy - Abstract
Small cell carcinoma is associated with a number of paraneoplastic syndromes. We report a case of a 42-year-old female who presented with primary laryngeal small cell carcinoma associated with concurrent paraneoplastic dermatomyositis and paraneoplastic angioedema secondary to acquired C1 esterase inhibitor deficiency. The patient required extensive treatment for her dermatomyositis including high-dose corticosteroid therapy and intravenous immunoglobulin followed by steroid-sparing disease-modifying immunosuppression. Her angioedema also required multiple lines of therapy including bradykinin inhibitors and human recombinant C1 esterase. We believe this is the first reported case of either of these paraneoplastic syndromes arising from an extrapulmonary small cell carcinoma and highlights the difficulty of its initial diagnosis as well as concurrent management. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Survival and cardiac toxicity in patients with HER2‐positive, metastatic breast cancer treated with trastuzumab in routine clinical practice.
- Author
-
Vasista, Anuradha, Ryan, Luke, Naher, Sayeda, Moylan, Eugene, Stockler, Martin R, Wilcken, Nicholas, and Kiely, Belinda E
- Subjects
- *
METASTATIC breast cancer , *CARDIAC patients , *HORMONE receptor positive breast cancer , *TRASTUZUMAB , *LIVER metastasis , *META-analysis - Abstract
Aims: We sought to describe survival outcomes and toxicities of trastuzumab in real‐world patients with HER2‐positive, metastatic breast cancer (MBC) and compare these to a recent systematic review of clinical trials. Methods: We searched the medical records of three Sydney cancer centers for patients with HER2‐positive, MBC starting trastuzumab from January 2001 to March 2017. We recorded patient, tumor, and treatment characteristics; survival times from start of palliative trastuzumab; and rates of cardiac toxicity. Survival distribution was summarized using the following percentiles (represented scenario): 90th (worst‐case), 75th (lower‐typical), 25th (upper‐typical), and 10th (best‐case). Survival times were compared to recent review of HER2‐positive MBC randomized trials. Factors associated with survival were assessed with Cox models. Results: Characteristics of the 126 patients were: median age 53 years, ER positive cancer (50%), de‐novo metastatic disease (23%), prior adjuvant trastuzumab (15%), liver metastases (37%), and brain metastases (23%). The median duration of first‐line trastuzumab was 11 months (interquartile range, (IQR) 5–27). Survival times in months (vs the systematic review) were: 90th percentile 8 (9); 75th percentile 16 (19); and median 34 (33). Follow‐up duration was insufficient to estimate the 25th and 10th percentiles, similar to the systematic review. Liver metastases were associated with shorter survival (HR = 1.74, 95% CI, 1.1‐2.76, P =.02). Seventy percent of patients had a baseline cardiac assessment. Five patients (3.9%) developed symptomatic cardiac toxicity, similar to clinical trials. Conclusion: Survival and cardiac toxicity rates for women starting trastuzumab in routine practice were comparable to clinical trials. Oncologists can use clinical trial data as a reference point when explaining survival outcomes to women with HER2‐positive MBC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
- Author
-
Wilson, Brooke E., Mok, Kelly, Kiely, Belinda E., Nguyen, Rebecca, and Moylan, Eugene
- Subjects
- *
BREAST tumor diagnosis , *ACUTE kidney failure , *BREAST tumors , *CELL receptors , *COMBINATION drug therapy , *CREATININE , *DRUG toxicity , *METASTASIS , *AROMATASE inhibitors , *TUMOR grading , *CELL cycle proteins , *BLOOD , *CHEMICAL inhibitors , *DISEASE risk factors - Abstract
Combination ribociclib and aromatase inhibitors are currently the preferred treatment in Australia for newly diagnosed hormone receptor positive metastatic breast cancer in the absence of visceral crisis. In our case series of 32 patients, 28% experienced grade 1 elevations in creatinine, a toxicity that was under‐recognised in large phase III studies. Creatinine rise appears to be due to a reversible inhibition of renal efflux transporters rather than an acute kidney injury in the majority of cases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Herbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis.
- Author
-
Li, Yuanqing, Zhu, Xiaoshu, Bensussan, Alan, Li, Pingping, Moylan, Eugene, Delaney, Geoff, and McPherson, Luke
- Abstract
Objective. This systematic review was conducted to evaluate the clinical effectiveness and safety of herbal medicine (HM) as an alternative management for hot flushes induced by endocrine therapy in breast cancer patients. Methods. Key English and Chinese language databases were searched from inception to July 2015. Randomized Controlled Trials (RCTs) evaluating the effects of HM on hot flushes induced by endocrine therapy in women with breast cancer were retrieved. We conducted data collection and analysis in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. Statistical analysis was performed with the software (Review Manager 5.3). Results. 19 articles were selected from the articles retrieved, and 5 articles met the inclusion criteria for analysis. Some included individual studies showed that HM can relieve hot flushes as well as other menopausal symptoms induced by endocrine therapy among women with breast cancer and improve the quality of life. There are minor side effects related to HM which are well tolerated. Conclusion. Given the small number of included studies and relatively poor methodological quality, there is insufficient evidence to draw positive conclusions regarding the objective benefit of HM. Additional high quality studies are needed with more rigorous methodological approach to answer this question. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Hypertrophic osteoarthropathy leading to the diagnosis of primitive neuroectodermal tumour (PNET).
- Author
-
Murphy, Conleth, Mohd Syahizul Nuhairy Mohd Sharial, Brennan, Neil, Lee, Garry, Moylan, Eugene, and O'Reilly, Seamus
- Subjects
- *
TUMORS , *DIAGNOSIS , *OLDER men , *MEDICAL radiography , *ONCOLOGY - Abstract
The article discusses the diagnosis of primitive neuroectodermal tumor in a 66-year-old man. His chest x-ray showed a lesion in the left lower zone. Computed tomography staging of thorax, abdomen and pelvis showed no evidence of metastatic disease. The patient was referred to the medical oncology services.
- Published
- 2008
- Full Text
- View/download PDF
10. Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study.
- Author
-
Hovey, Elizabeth, Gabriel, Gabriel, George, Monika, Shapiro, Jeremy, Chern, Boris, and Moylan, Eugene
- Subjects
- *
PROSTATE cancer , *PROGNOSIS , *DOCETAXEL , *PROSTATE-specific antigen , *ONCOLOGY , *METASTASIS , *DRUG therapy - Abstract
Background: Hormone-refractory prostate cancer (HRPC) is associated with a poor prognosis and has historically been considered relatively chemoresistant. Emerging data demonstrate clinical benefit with the use of docetaxel in HRPC, culminating in two recent published phase III studies demonstrating survival benefit. Currently, docetaxel is registered but not reimbursed for HRPC in Australia. Aim: To retrospectively review prostate-specific antigen (PSA) response rate, and survival following the use of docetaxel for metastatic HRPC. Methods: Retrospective audit of the use of docetaxel for HRPC from 1 January 2001 to 1 April 2004 in three medical oncology practices. Demographic data, baseline PSA, ECOG (Eastern Cooperative Oncology Group) Performance Status, sites of disease, number of cycles received and PSA response rates were collected. Results: Thirty five patients (median age, 71 years; range, 50–88) had an ECOG status of 0 (eight), 1 (20) and 2 (seven). The mean duration from initial prostate cancer diagnosis to start of docetaxel was 5.4 years (range, 0.2–13.5 years). The mean baseline PSA doubling time, available for 29/35 patients, was 1.9 months (range, 0.4–4.9). The median number of metastatic sites was 1 (range, 1–4): bone (34 patients), lymph nodes (10), liver (seven) and lung (seven). Twelve patients were chemotherapy naive; 23 had received prior chemotherapy (21/23 received mitoxantrone). Twenty patients received docetaxel three times weekly; 15 were on weekly schedules. Their mean dose density was 23 mg/m2/week. Patients received an average of 3.2 months of treatment (range, 0.2–11.8). There were 170 recorded toxicities, 13 of which were grade 3–4, and two likely treatment-related deaths (sepsis). Twelve patients (34%) had >50% PSA response (four were chemotherapy naive); of these 12 responders, seven patients had a >75% PSA response (four chemotherapy naive). Median survival from start of docetaxel was 8 months with 37% alive at 12 months and 23% alive at 24 months. Conclusion: Docetaxel is active in HRPC (in both chemotherapy naive and exposed patients) with a predictable toxicity profile. More research is warranted to identify predictors of response and toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
11. Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer.
- Author
-
Davis, Alison J., Brew, Sue, Gebski, Val J., Lewis, Craig R., Moylan, Eugene, Parnis, Francis X., and Ackland, Stephen P.
- Subjects
- *
BREAST cancer , *ANTHRACYCLINES , *AMINO compounds , *AMINOGLYCOSIDES , *STANDARD deviations - Abstract
Background: Capecitabine and i.v. vinorelbine are both active in metastatic breast cancer with non-overlapping toxicities. This study examined the efficacy and safety of the combination of these agents in patients with pretreated metastatic breast cancer. Methods: Patients previously treated for breast cancer, maximum of one prior metastatic regimen, received capecitabine 1000 mg/m2 b.d. for days 1–14 and vinorelbine 25 mg/m2 i.v. days 1 and 8 every 21 days. All patients had measurable disease and adequate baseline organ function. The primary endpoint was response and secondary endpoints time to progression, duration of response, survival and safety. Results: Twenty-two patients (median age 56 years) received a median of six cycles. All patients had received anthracyclines and 64% taxanes. Objective responses were seen in 7/21 (33%, 95% confidence interval [CI] 18–57%), with two complete responses; stable disease was seen in 5/21 (24%, 95% CI 8–42%). Median duration of response was 6.9 months (95% CI 4.7–13.1), time to progression was 5.8 months (95% CI 2.8–6.8) and survival was 13.5 months (95% CI 6.9–19.9). The median dose intensity of vinorelbine was 75% of the intended dose and of capecitabine 85% of intended dose. The main toxicity was myelosuppression including 16 episodes of G3–4 neutropenia in 11 patients (50%). Other toxicities were generally mild to moderate. Conclusion: The combination of capecitabine and i.v. vinorelbine is active and well tolerated in patients with pretreated metastatic breast cancer. The recent availability of oral vinorelbine provides an opportunity to explore a fully oral combination. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
12. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer
- Author
-
Clarke, Stephen J., Boyer, Michael J., Millward, Michael, Underhill, Craig, Moylan, Eugene, Yip, Desmond, White, Shane, Childs, Annabel, Beale, Phillip, Latz, Jane, Suri, Ajit, and Iglesias, Jose L.
- Subjects
- *
LUNG cancer , *SMALL cell lung cancer , *PHARMACOKINETICS , *ANTINEOPLASTIC agents , *CANCER chemotherapy - Abstract
Summary: Purpose:: Pemetrexed and vinorelbine are active antineoplastic agents in non-small cell lung cancer (NSCLC). Phase I objectives include maximum tolerated dose (MTD) and recommended phase II dose determination, and pharmacokinetics of the pemetrexed–vinorelbine doublet in locally advanced or metastatic solid tumor patients (pts). Phase II objectives include tumor response evaluation, efficacy, and toxicity for first-line treatment of advanced NSCLC. Experimental design:: Phase I pts received pemetrexed (day 1, 300–700mg/m2) and vinorelbine (days 1 and 8, 15–30mg/m2) every 21 days. Pharmacokinetics determined at cycle 1. Beginning with dose-level 3, folic acid and Vitamin B12 supplementation were given. Results:: Thirty-one phase I pts were enrolled. MTD was pemetrexed 700mg/m2 and vinorelbine 30mg/m2; and recommended phase II dose was pemetrexed 500mg/m2 and vinorelbine 30mg/m2. When administered in combination, pemetrexed and vinorelbine pharmacokinetics were consistent with single-agent administration. Thirty-seven (36 chemonaive) phase II NSCLC pts received pemetrexed–vinorelbine. Evaluable tumor response was 40%, with intent-to-treat 38%. One drug-related death occurred from febrile neutropenia with Staphylococcal infection. Grade 3/4 hematologic toxicities were neutropenia (65%) and febrile neutropenia (11%), while prevalent grade 3/4 non-hematologic toxicity was fatigue (27%). Conclusion:: The pemetrexed–vinorelbine combination is well tolerated and shows activity as first-line treatment in advanced NSCLC patients. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
13. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
- Author
-
Punt, Cornelis J A, Nagy, Attila, Douillard, Jean-Yves, Figer, Arie, Skovsgaard, Torben, Monson, John, Barone, Carlo, Fountzilas, George, Riess, Hanno, Moylan, Eugene, Jones, Delyth, Dethling, Juergen, Colman, Jessica, Coward, Lorna, and MacGregor, Stuart
- Subjects
- *
COLON cancer treatment , *MONOCLONAL antibodies , *FLUOROURACIL , *FOLINIC acid , *GLYCOPROTEINS , *THERAPEUTICS - Abstract
Summary: Background: Edrecolomab is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary data suggested that it might be of use in the adjuvant treatment of patients with resected stage III colon cancer. We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients. Methods: After surgery, 2761 patients were randomly assigned edrecolomab plus fluorouracil-folinic acid (combination therapy [n=912]); fluorouracil-folinic acid alone (chemotherapy [n=927]); or edrecolomab alone (edrecolomab monotherapy [n=922]). Patients were assessed for survival and disease recurrence after surgery. The primary endpoint tested the hypothesis that combination therapy improved overall survival relative to chemotherapy. The key secondary endpoint was to test whether edrecolomab monotherapy was non-inferior to chemotherapy in terms of disease-free survival. Analysis was by intention to treat. Findings: Median follow-up time was 26 months (IQR 20-36). 3-year overall survival on combination therapy was no different from that on chemotherapy (74.7% vs 76.1%, hazard ratio 0.94 [95% CI 0.76-1.15], p=0.53). Disease-free survival was significantly lower on edrecolomab monotherapy than on chemotherapy (53.0% vs 65.5%, 0.62 [0.53-0.73], p<0.0001). Hypersensitivity reactions occurred in 452 (25%) patients receiving edrecolomab, causing treatment discontinuation in 71 (4%). The addition of edrecolomab to chemotherapy did not increase neutropenia, diarrhoea, or mucositis. Interpretation: The addition of edrecolomab to fluorouracil and folinic acid in the adjuvant treatment of resected stage III colon cancer does not improve overall or disease-free survival, and edrecolomab monotherapy is associated with significantly shorter overall and disease-free survival than fluorouracil and folinic acid and is... [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
14. Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
- Author
-
Tervonen, Hanna E., Chen, Tina Y. T., Lin, Enmoore, Boyle, Frances M., Moylan, Eugene J., Della‐Fiorentina, Stephen A., Beith, Jane, Johnston, Amy, and Currow, David C.
- Subjects
- *
BREAST cancer prognosis , *ANALYSIS of variance , *BREAST tumors , *CHI-squared test , *COMBINED modality therapy , *CONFIDENCE intervals , *STATISTICAL correlation , *HOSPITAL care , *HOSPITAL emergency services , *MEDICAL protocols , *NEUTROPENIA , *RISK assessment , *DOCETAXEL , *TRASTUZUMAB , *LOGISTIC regression analysis , *PROPORTIONAL hazards models , *RETROSPECTIVE studies , *CYCLOPHOSPHAMIDE , *CARBOPLATIN , *KAPLAN-Meier estimator , *ODDS ratio - Abstract
Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population‐based and clinical cancer registries (2008–2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ≥18 years receiving adjuvant chemotherapy for early‐stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6 months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan–Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3‐weekly (OR 1.71, 95% confidence interval [CI] 1.24–2.37 and OR 1.47, 95% CI 1.17–1.85 respectively). Five‐year overall survival was similar for women who were (92.2%, 95% CI 90.7–93.8) and were not hospitalised (93.1%, 95% CI 92.1–94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel‐containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.